CrkL knockdown also inhibited in vivo tumor growth in head and neck squamous cell carcinoma [46], rhabdomyosarcoma [33], hepatocellular carcinoma [39], and colorectal cancer [47] cells. Here, CRKL is linked to rhabdomyosarcoma.